期刊文献+

良好的制药企业偏差管理 被引量:4

Good deviation management in pharmaceutical enterprise
下载PDF
导出
摘要 介绍制药企业常见的偏差管理缺陷,并分别从制药企业和药品监管的角度,分析导致这些缺陷的原因。对如何建立一个良好的制药企业偏差管理流程进行阐述,包括对偏差报告的要求、偏差的调查程序、根本原因的确定、涉及批产品或物料的处置、偏差质量风险评估、整改措施和预防措施(CAPA)制定、调查结论的确认和批准、CAPA实施的跟踪及有效性回顾。 The common deviation defciencies in pharmaceutical enterprises were introduced and the causes of these deficiencies were analyzed from the working experience in pharmaceutical industry and the perspective of drug regulation inspector. How to set up a good deviation management process in pharmaceutical enterprises was also described, including the requirement of deviation report, the procedure for deviation investigation, the determination of root cause, the disposal of batch products or materials involved, the assessment of quality risk for the deviation, the formulation of corrective action and preventive action (CAPA), the confrmation and approval of the investigation fndings, the implementation of CAPA track and the review of its efectiveness.
作者 谭建新 丁力承 付秋雁 TAN Jianxin;DING Licheng;FU Qiuyan(Shanghai Center of Drug Evaluation and Inspection, Shanghai 201203, China)
出处 《上海医药》 CAS 2018年第9期47-50,60,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 偏差 评估 整改措施和预防措施 deviation evaluation corrective action and preventive action
  • 相关文献

参考文献8

二级参考文献31

  • 1胡谦谦,梁毅.药品生产的偏差分析[J].上海医药,2007,28(8):366-368. 被引量:3
  • 2陈维丹.论企业质量体系的动态运作[J].木材工业,2005,19(6):25-27. 被引量:1
  • 3缪德骅.纵论GMP引领药品生产的观念更新[J].上海医药,2006,27(3):102-104. 被引量:9
  • 4温艳华.无菌冻干药品生产偏差的处理[J].海峡药学,2006,18(5):24-26. 被引量:5
  • 5丁静,胡廷熹,梁毅.药品生产中的变更控制[J].上海医药,2007,28(7):321-324. 被引量:4
  • 6U.S.Department of Health and Human Services.Food and DrugAdministration.Center for Drug Evaluation and Research(CDER).Guidance for Industry:Investigation Out-of-Specification(OOS)TestResults for Pharmaceutical Production[M].Pharmaceutical cGMPs,October 2006.
  • 7Anthony C.Celeste. Practical Aspects of OOS Investigations[J]. FDA News & Infromation, 2007, Volume 8, Number 17.
  • 8The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use(ICH).Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients(Q7A)[S].2000.
  • 9The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use(ICH).Quality Risk Management(Q9)[S].2005.
  • 10Anthony C Celeste.Practical Aspects of OOS Investigations[J].FDA News&Infromation,2007,Volume 8,Number 17.

共引文献36

同被引文献32

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部